Evaluating rezatapopt*, a first-in-class p53 reactivator, as a treatment for TP53 Y220Cmutant locally advanced and metastatic solid tumours The experts discuss: TP53 Y220C mutation and rationale for targeted therapy Study overview and practice implications, spotlighting ovarian cancer Testing strategies for early and accurate patient identification Video in this post *Rezatapopt is an investigational agent which is not approved by a regulatory agency This programme has been sponsored by PMV Pharma #MedicalEducation #Oncology Update from AACRNCIEORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220Cmutant solid tumours To view or add a comment, sign in 26,256 followers
We'll review your health history, discuss your struggles and goals, and determine if you're a candidate for our program
Este apartado aborda su eficacia, desde las primeras formulaciones hasta los desarrollos ms recientes, resaltando su influencia en la reduccin ponderal y su potencial en el manejo de la obesidad (tabla 1 y fig
Ingredientes naturales como la Berberina, Reducose, Gominolas Digestivas, Protena & EAAs, y Omega-3 Vegano ayudan a activar vas similares que regulan la saciedad y el azcar en sangre, ofreciendo una alternativa segura y natural a la Semaglutida o Tirzepatida
Red indicates decreased transitions on drug